Keywords: AstraZeneca, Vandetanib, Thyroid cancer, USA launch, Zactima

AstraZeneca debuts vandetanib for medullary thyroid cancer in USA

Article | 26 April 2011

Print This

Anglo-Swedish drug major AstraZeneca (LSE: AZN) said yesterday that its orphan drug vandetanib is now available to US patients for ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in